O'Dell Group’s Vertex Pharmaceuticals VRTX Stock Holding History

O'Dell Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	-$3K	–	500
2022 Q2	$3K	Buy	10 +4	+67%	+$1.07K	﹤0.01%	391
2022 Q1	$2K	Hold	6	–	–	﹤0.01%	458
2021 Q4	$1K	Hold	6	–	–	﹤0.01%	499
2021 Q3	$1K	Buy	+6	New	+$1.17K	﹤0.01%	476

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

O'Dell Group's VRTX Position: Q3 2022 in Review

O'Dell Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 10 shares — an estimated $3K sold.

O'Dell Group first reported a position in VRTX in Q3 2021 and held it in 4 quarters. The position peaked at $3K in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

O'Dell Group reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
O'Dell Group sold 10 Vertex Pharmaceuticals shares in Q3 2022, an estimated $3K.
O'Dell Group first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 4 quarters.
O'Dell Group's Vertex Pharmaceuticals position peaked at $3K in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on O'Dell Group's 13F filing for Q3 2022, filed 8 Nov 2022.